Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.58 |
| ▸ | GGT1 | P19440 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31618292 | 1.00 | CFD (0.69) | CFDKDM4EALDH1A1HSD17B10TDP1 | |
| Methoxymethane SCHEMBL5317565 | 0.97 | CFD (0.65) | CFDKDM4EALDH1A1HSD17B10TDP1 | |
| Aspirin SCHEMBL22972824 | 0.92 | KDM4E (0.73) | CFDKDM4EALDH1A1HSD17B10TDP1 | |
| SCHEMBL8699559 | 0.88 | KDM4E (0.73) | CFDKDM4EALDH1A1HSD17B10TDP1 | |
| SCHEMBL4737527 | 0.86 | ALDH1A1 (0.69) | CFDKDM4EALDH1A1HSD17B10TDP1 | |
| SCHEMBL3803677 | 0.85 | ALDH1A1 (0.50) | CFDKDM4EALDH1A1HSD17B10TDP1 | |
| SCHEMBL9318003 | 0.83 | CFD (0.47) | CFDKDM4EALDH1A1HSD17B10TDP1 | |
| SCHEMBL5317567 | 0.83 | GAA (0.56) | CFDKDM4EALDH1A1HSD17B10TDP1 | |
| SCHEMBL10764467 | 0.82 | CFD (0.48) | CFDKDM4EALDH1A1HSD17B10TDP1 | |
| Aspirin SCHEMBL2467028 | 0.82 | KDM4E (0.67) | CFDKDM4EALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145763-A1 | LOW THC HEMP EXTRACT AND METHOD OF TREATMENT OR PREVENTION OF AN EYE DISEASE | EYE CO PTY LTD. (AU) | 2021-05-20 | — | — | US | claimed |
| EP-3773651-A1 | LOW THC HEMP EXTRACT AND METHOD OF TREATMENT OR PREVENTION OF AN EYE DISEASE | Eye Co Pty Ltd. (AU) | 2021-02-17 | — | — | EP | claimed |
| WO-2019191800-A1 | LOW THC HEMP EXTRACT AND METHOD OF TREATMENT OR PREVENTION OF AN EYE DISEASE | EYE CO PTY LTD (AU) | 2019-10-10 | — | — | WO | claimed |
| US-8956647-B2 | Pellet formulation for the treatment of the intestinal tract | DR. FALK PHARMA GMBH (DE) | 2015-02-17 | — | — | US | claimed |
| US-8911778-B2 | Pellet formulation for the treatment of the intestinal tract | DR. FALK PHARMA GMBH (DE) | 2014-12-16 | — | — | US | claimed |
| US-8496965-B2 | Pellet formulation for the treatment of the intenstinal tract | DR. FALK PHARMA GMBH (DE) | 2013-07-30 | — | — | US | claimed |
| US-20130177650-A1 | PELLET FORMULATION FOR THE TREATMENT OF THE INTESTINAL TRACT | DR. FALK PHARMA GMBH | 2013-07-11 | — | — | US | claimed |
| US-20120308659-A1 | PELLET FORMULATION FOR THE TREATMENT OF THE INTENSTINAL TRACT | OTTERBECK NORBERT (DE) | 2012-12-06 | — | — | US | claimed |
| WO-2005030224-A1 | NITROSYLATED ANALGESIC AND/OR ANTI-INFLAMMATORY DRUGS HAVING ANTIVIRAL ACTIVITY | NICOX S.A. (FR) | 2005-04-07 | — | — | WO | claimed |
| US-20040072798-A1 | Compositions comprising cyclodextrins and no-releasing drugs | NICOX S.A. (FR) | 2004-04-15 | — | — | US | claimed |
| EP-1347782-A1 | COMPOSITIONS COMPRISING CYCLODEXTRINS AND NO-RELEASING DRUGS | Nicox S.A. (FR) | 2003-10-01 | — | — | EP | claimed |
| WO-2002053188-A1 | COMPOSITIONS COMPRISING CYCLODEXTRINS AND NO-RELEASING DRUGS | NICOX S.A. (FR) | 2002-07-11 | — | — | WO | claimed |
| CN-1356981-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-07-03 | — | — | CN | claimed |
| EP-1219306-A1 | Compositions comprising cyclodextrins and NO- releasing drugs | NICOX S.A. (FR) | 2002-07-03 | — | — | EP | claimed |
| EP-0504560-A1 | Preparation of anhydride-capped polyphenylene ether in a melt process | GENERAL ELECTRIC COMPANY (US) | 1992-09-23 | — | — | EP | claimed |
| EP-0501154-A2 | Polyphenylene ether-polyamide compositions | GENERAL ELECTRIC COMPANY (US) | 1992-09-02 | — | — | EP | claimed |
| US-5141999-A | PREPARATION OF ANHYDRIDE-CAPPED POLYPHENYLENE ETHER IN A MELT PROCESS | GENERAL ELECTRIC COMPANY (US) | 1992-08-25 | — | — | US | claimed |
| US-5140077-A | Copolymers of an acetyl or phenyl 4-aminosalicylic acid trimellitamide-end capped polyphenylene ether and a polyamide as compatilizers for polyether/amide blends; heat and oxidation resistance | GENERAL ELECTRIC COMPANY (US) | 1992-08-18 | — | — | US | claimed |
| JP-5066221-A | — | — | None | — | — | JP | disclosed |
| EP-0148752-A2 | Protease inhibitors | G.D. Searle & Co. (US) | 1985-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072798-A1 | Compositions comprising cyclodextrins and no-releasing drugs | NOS1, NOS2, NOS3 | CFD 694/4885KDM4E 4029/4885ALDH1A1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.